Sarepta Therapeutics, Inc.
Records under this name other than the patents Sarepta Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 100 patents it holds.
Back to Sarepta Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,326,992 | Methods for Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human Lmna now held by Progeria Research Foundation, Inc. In force · High confidence | In force | High confidence | |
| US 9,833,468 | Methods for Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human Lmna now held by University of Maryland In force · Medium confidence | In force | Medium confidence | |
| US 10,398,721 | Methods for Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human Lmna now held by University of Maryland In force · High confidence | In force | High confidence | |
| US 10,822,608 | Oligonucleotide Analogues Targeting Human Lmna now held by Progeria Research Foundation, Inc. In force · High confidence | In force | High confidence | |
| US 11,802,283 | Oligonucleotide Analogues Targeting Human Lmna now held by Progeria Research Foundation, Inc. In force · High confidence | In force | High confidence | |
| US 12,590,306 | Processes for Preparing Phosphorodiamidate Morpholino Oligomers via Fast-Flow Synthesis now held by Massachusetts Institutes of Technology In force · High confidence | In force | High confidence | |
| US 12,502,432 | Bicyclic Peptide Oligonucleotide Conjugates now held by Massachusetts Institute of Technology In force · High confidence | In force | High confidence | |
| US 12,370,261 | Chimeric Peptides for Antisense Delivery now held by Massachusetts Institute of Technology In force · High confidence | In force | High confidence | |
| US 8,030,291 | Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection Term ended Term ended Nov 21, 2026 · High confidence | Term ended | Term ended Nov 21, 2026 | High confidence |
| US 8,030,292 | Antisense Antiviral Compounds and Methods for Treating a Filovirus Infection Term ended Term ended Nov 21, 2026 · High confidence | Term ended | Term ended Nov 21, 2026 | High confidence |